{
  "doc_id": "06_41927_2025_Article_585",
  "doc_filename": "06_41927_2025_Article_585.pdf",
  "trial_ids": [],
  "study_design": {
    "phase": null,
    "design_type": "single-arm",
    "blinding": null,
    "randomization_ratio": null,
    "allocation": null,
    "sample_size": 220,
    "actual_enrollment": 220,
    "duration_months": 96,
    "treatment_arms": [],
    "control_type": null,
    "setting": "Amir Alam Hospital, Tehran, Iran",
    "sites_total": 1,
    "countries_total": 1,
    "periods": [],
    "evidence": [
      {
        "page": 2,
        "section_header": null,
        "quote": "This is a retrospective cohort study involving Iranian patients diagnosed with GPA",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "06_41927_2025_Article_585"
      },
      {
        "page": 1,
        "section_header": null,
        "quote": "clinical records of 220 patients with a confirmed diagnosis of GPA who were referred to Amir Alam Hospital between 2013 and 2021 were reviewed",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "06_41927_2025_Article_585"
      },
      {
        "page": 2,
        "section_header": null,
        "quote": "The study includes all patients aged 16 years or older who were either hospitalized or seen in the rheumatology outpatient clinic at Amir Alam Hospital between 2013 and 2021",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "06_41927_2025_Article_585"
      }
    ]
  },
  "eligibility_inclusion": [
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "age > 16 years old",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "inclusion",
        "category": "age",
        "derived": {
          "operator": ">",
          "value": 16,
          "unit": "years"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "age > 16 years old",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "at least 3 months follow up",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "inclusion",
        "category": "other",
        "derived": {
          "operator": ">=",
          "value": 3,
          "unit": "months"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "at least 3 months follow up",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "GPA diagnosis based on the algorithm",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "inclusion",
        "category": "diagnosis",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "GPA diagnosis based on the algorithm",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "Iranian patients diagnosed with GPA according to the 1990 American College of Rheumatology (ACR) criteria and the European Medicines Agency (EMA) algorithm",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "inclusion",
        "category": "diagnosis",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "Iranian patients diagnosed with GPA according to the 1990 American College of Rheumatology (ACR) criteria and the European Medicines Agency (EMA) algorithm",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "gave written consent for use of their data",
      "section": "eligibility",
      "page": 4,
      "structured_data": {
        "type": "inclusion",
        "category": "consent",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 4,
          "quote": "gave written consent for use of their data",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    }
  ],
  "eligibility_exclusion": [
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "patients meet criteria for EGPA",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "exclusion",
        "category": "diagnosis",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "patients meet criteria for EGPA",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "patient has small vessels features",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "exclusion",
        "category": "diagnosis",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "patient has small vessels features",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "ANCA + but no GPA features",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "exclusion",
        "category": "biomarker",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "ANCA + but no GPA features",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "biopsy or imaging evidence consistent with PAN",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "exclusion",
        "category": "diagnosis",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "biopsy or imaging evidence consistent with PAN",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "Patients with incomplete diagnostic information that cannot be retrieved through follow-up phone calls",
      "section": "eligibility",
      "page": 2,
      "structured_data": {
        "type": "exclusion",
        "category": "other",
        "derived": null
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 2,
          "quote": "Patients with incomplete diagnostic information that cannot be retrieved through follow-up phone calls will be excluded",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    }
  ],
  "epidemiology": [],
  "patient_journey": [],
  "endpoints": [
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Frequency of GI involvement",
      "section": "endpoints",
      "page": 1,
      "structured_data": {
        "type": "primary",
        "name": "Frequency of GI involvement",
        "measure": "Proportion of GPA patients with gastrointestinal manifestations",
        "timepoint": "During follow-up period (2013-2021)",
        "analysis_method": "Descriptive statistics"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 1,
          "quote": "This study aimed to assess the frequency and types of Gl involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatment response.",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Types of GI involvement",
      "section": "endpoints",
      "page": 1,
      "structured_data": {
        "type": "primary",
        "name": "Types of GI involvement",
        "measure": "Clinical manifestations of gastrointestinal involvement",
        "timepoint": "At diagnosis and during follow-up",
        "analysis_method": "Descriptive analysis"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 1,
          "quote": "This study aimed to assess the frequency and types of Gl involvement in patients with GPA and to examine their relationship with disease severity, prognosis, and treatment response.",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Disease severity comparison",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "secondary",
        "name": "Disease severity comparison",
        "measure": "Birmingham Vasculitis Activity Score (BVAS)",
        "timepoint": "At diagnosis and after follow-up (median 19 months)",
        "analysis_method": "Student's t-test and ANCOVA adjustment"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "At the time of diagnosis, the mean BVAS score was significantly higher in patients with GI manifestations compared to those without (21.0 + 10.13 vs. 15.8 + 7.43; p =0.004). Similarly, after follow-up time with median of 19 months, patients with GI symptoms continued to exhibit higher disease activity (8.47+9.24 vs. 4.43 +7.72; p=0.042).",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Treatment response",
      "section": "endpoints",
      "page": 3,
      "structured_data": {
        "type": "secondary",
        "name": "Treatment response",
        "measure": "BVAS-WG scores for complete remission, partial remission, and relapse",
        "timepoint": "During treatment and follow-up",
        "analysis_method": "BVAS-WG scoring system"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 3,
          "quote": "Treatment response: assessed using BVAS-WG scores. Complete remission is defined as a BVAS-WG score of zero after treatment, partial remission as a>50% reduction in BVAS-WG, and relapse as any increase in BVAS-WG.",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Time to first relapse",
      "section": "endpoints",
      "page": 1,
      "structured_data": {
        "type": "secondary",
        "name": "Time to first relapse",
        "measure": "Time from diagnosis to first relapse",
        "timepoint": "During follow-up period",
        "analysis_method": "Comparison between groups"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 1,
          "quote": "a shorter time to first relapse (mean 5.2 vs. 10.3 months, p=0.041) compared to those without Gl symptoms.",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Mortality risk",
      "section": "endpoints",
      "page": 1,
      "structured_data": {
        "type": "secondary",
        "name": "Mortality risk",
        "measure": "Hazard ratio for mortality",
        "timepoint": "During follow-up period",
        "analysis_method": "Hazard ratio calculation"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 1,
          "quote": "a markedly increased mortality risk (hazard ratio= 3.24, p< 0.001)",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Relapse rates",
      "section": "endpoints",
      "page": 3,
      "structured_data": {
        "type": "secondary",
        "name": "Relapse rates",
        "measure": "Proportion of patients experiencing relapse",
        "timepoint": "During follow-up period",
        "analysis_method": "Hazard ratios comparison"
      },
      "confidence": 0.44,
      "evidence": [
        {
          "page": 3,
          "quote": "Prognostic outcomes: relapse and mortality rates. Hazard ratios will be calculated to compare relapse and mortality rates between patients with and without gastrointestinal involvement.",
          "source_node_id": null,
          "source_doc_id": "06_41927_2025_Article_585"
        }
      ]
    }
  ],
  "sites": [
    {
      "field_type": "STUDY_SITE",
      "text": "Iran",
      "section": "sites",
      "page": null,
      "structured_data": {
        "country": "Iran",
        "site_count": 1
      },
      "confidence": 0.85,
      "evidence": []
    }
  ],
  "operational_burden": {
    "invasive_procedures": [
      {
        "name": "biopsy",
        "timing": [
          "eligibility requirement"
        ],
        "timing_days": [
          -1
        ],
        "optional": false,
        "purpose": "diagnosis_confirmation",
        "is_eligibility_requirement": true,
        "evidence": [
          {
            "page": 2,
            "section_header": null,
            "quote": "require to at least biopsy proven vasculitis",
            "char_start": null,
            "char_end": null,
            "bbox": null,
            "source_node_id": null,
            "source_doc_id": "06_41927_2025_Article_585"
          }
        ]
      }
    ],
    "visit_schedule": {
      "total_visits": null,
      "visit_days": [],
      "frequency": null,
      "duration_weeks": null,
      "scheduled_visits": [],
      "pre_randomization_days": [],
      "on_treatment_days": [],
      "follow_up_days": [],
      "evidence": []
    },
    "central_lab_required": false,
    "central_lab": null,
    "special_sample_handling": [],
    "vaccination_requirements": [],
    "background_therapy": [],
    "concomitant_meds_allowed": [],
    "run_in_duration_days": null,
    "run_in_requirements": [],
    "burden_score": null,
    "site_complexity_score": null,
    "hard_gates": [
      "biopsy requirement"
    ]
  },
  "screening_flow": null,
  "extraction_timestamp": "2026-02-04T15:26:11.269488"
}